We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Toumaz | LSE:TMZ | London | Ordinary Share | KYG6390E1070 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.125 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
02/7/2016 10:08 | doh. bloody links: | juleshoddy | |
02/7/2016 10:07 | hxxp://presstelegrap | juleshoddy | |
30/6/2016 13:24 | Is there news on the way ??? | dickiebird2 | |
30/6/2016 10:44 | hxxp://www.avhub.com | jimboceh | |
28/6/2016 20:30 | Currency risks The Group is exposed to foreign exchange risk. Most of its products are priced in US$ and, whilst the majority of its third party cost base is also denominated in US$, a large element of its labour cost is borne in sterling and with the setting up of the research centre in Timisoara, Romania an element is borne in Romanian LEU. Management aim to keepareasonable balance of cash in both US$ and £GBP to cover the cost base. The Group does not seek to hedge its foreign exchange risk and the Directors consider that the exposure to movements in foreign currencies is not significant. At the time when the Directors consider that exposure to foreign exchange trading risks becomes significant they will seek to adopt appropriate hedging strategies and products. | nod | |
28/6/2016 08:13 | Weaker sterling should accelerate profitability. | chillpill | |
26/6/2016 14:43 | Hope your right !! | dickiebird2 | |
26/6/2016 11:42 | nod - I thought the same - firms of international lawyers must be a strong buy. | supernumerary | |
26/6/2016 11:00 | Toumaz has 111 world patentshttps://paten | nod | |
26/6/2016 10:53 | Rumour has it the Sensium is being given away in exchange for future royalties. I doubt this is creating shareholder value. Truth is that Sensium has been a scapegoat for poor leadership. Of the £17m raised a couple of years ago, very little has been allocated to the development and progression of Sensium, and it has been a missed opportunity where TMZ had some genuine IP. Watch out on the consumer audio side as well, where there is little investment in IP that will create a sustainable future despite the strength of DAB. The company could have a bright future, but it needs a new strategy and new leadership. | 1activeinvestor | |
26/6/2016 10:24 | I've read a few non-UK media articles in the last couple of days with Government insiders voicing their opinion that Brexit is a massive project, requiring skills that are in short supply in the UK as most of these roles have been performed by Brussels. UK has been involved but only one tenth or less of the resource.To me it reads like a big company that outsourced its IT some five or 10 years ago and would like to bring it back in-house as it is being poorly-served and finds outsourcing much more expensive than it was led to believe in the proposal.It's a massive project requiring a huge number of highly skilled resources that are no longer available at home because they were not required and are very expensive from overseas. AFAIK no large company has done this. No country has done this. The impact on the UK will be massively increased central government costs, and most likely less money for health and education. | nod | |
26/6/2016 09:21 | A sale of sensium will stop the slide! | trek3 | |
25/6/2016 15:50 | By the sounds of it the NHS is not going to get the funding promised by the vote out campaigners so I think even if trials are successful for sensium it will be put on the back shelf by the NHS. We can only hope it is taken up abroad. Cash generating does not mean being in profit. The share price has been sliding over the months and at the moment I can`t see anything stopping the slide. | sabre6 | |
25/6/2016 10:56 | AIM is an imperfect market and that creates opportunity. | chillpill | |
25/6/2016 10:39 | I would not hold your breath I think the share price says it all! | sabre6 | |
24/6/2016 16:58 | The annual report said "We expect the Group to be cash flow break-even by the middle of 2016.". If they can indeed manage that then they are very undervalued and even more so with a weak pound. I wait eagerly and nervously for the report on SensiumVitals, expected to be completed 'in the middle of 2016'. Could that blows a hole in our capital? | gnnmartin | |
24/6/2016 12:57 | Biggest potential market is USA, so a weak pound is an advantage, in the EU, it depends on the deal our government strike on tariffs. | trek3 | |
24/6/2016 10:48 | Not sure brexit has any effect on TMZ other than most their sales are overseas so should give them a benefit when translating back into sterling. | chillpill | |
23/6/2016 09:37 | Somebody has just bought a wedge, 900k first decent buy in ages, made me smile! | trek3 | |
23/6/2016 09:16 | Come on TMZ give us something to smile about !!! | dickiebird2 | |
19/6/2016 12:11 | This share was supposed to generate cash by the middle of this year! Not according to the share price. | sabre6 | |
19/6/2016 11:18 | And before that in 2009 the trial at London St Mary's Hospital with partner Carefusion (who had deep pockets).St Mary's was where penicillin was discovered. Pity they didn't discover Sensium. | nod | |
19/6/2016 11:05 | life of crime has a point in there,it's always about the big firms and they often,it seems to me,let the little firms do all the hard work, wait until the firm is on its knees and then take it out,at a fraction of its worth, as we the investors get more disillusioned and capitulate and they can afford to wait. Of course it has come at a time when the NHS has to justify every penny, couple that alongside the red-tape and here we are today. IMO | hazl |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions